التفاصيل البيبلوغرافية
| العنوان: |
EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer. |
| المؤلفون: |
Chan, Ann M., Aguirre, Brian, Liu, Lucia, Mah, Vei, Balko, Justin M., Tsui, Jessica, Wadehra, Navin P., Moatamed, Neda A., Khoshchehreh, Mahdi, Dillard, Christen M., Kiyohara, Meagan, Elshimali, Yahya, Chang, Helena R., Marquez-Garban, Diana, Hamilton, Nalo, Pietras, Richard J., Gordon, Lynn K., Wadehra, Madhuri |
| المصدر: |
Cancers; Apr2024, Vol. 16 Issue 8, p1481, 15p |
| مصطلحات موضوعية: |
BREAST cancer prognosis, THERAPEUTIC use of antineoplastic agents, IN vitro studies, TISSUE arrays, DOCETAXEL, DRUG resistance in cancer cells, RESEARCH funding, BREAST tumors, TUMOR markers, XENOGRAFTS, IN vivo studies, CANCER patients, DESCRIPTIVE statistics, CANCER chemotherapy, MICE, CELL lines, CELL culture, GENE expression profiling, OVERALL survival |
| مستخلص: |
Simple Summary: Breast cancer (BC) ranks as among the top two commonly diagnosed cancers in women worldwide. Triple-negative breast cancer (TNBC) is recognized globally as the most lethal subtype of BC, with patients often building resistance to conventional chemotherapy treatments. This study assesses the relationship between taxane-based chemotherapy resistance in BC and the oncoprotein epithelial membrane protein 2 (EMP2), with an emphasis on the aggressive TNBC group. Analyses of preclinical models and human tissue samples reveal that EMP2 may not only be used to predict patient response to taxanes but also serve as a therapeutic target for resistant disease. Our findings demonstrate a correlation between elevated EMP2 expression post-chemotherapy and reduced survival outcomes and reveal that targeting EMP2 in conjunction with chemotherapy yields a synergistic reduction in TNBC tumor volume. Thus, results shed light on a novel biomarker for guiding the personalized, targeted treatment of intractable and recurrent TNBC. Breast cancer (BC) remains among the most commonly diagnosed cancers in women worldwide. Triple-negative BC (TNBC) is a subset of BC characterized by aggressive behavior, a high risk of distant recurrence, and poor overall survival rates. Chemotherapy is the backbone for treatment in patients with TNBC, but outcomes remain poor compared to other BC subtypes, in part due to the lack of recognized functional targets. In this study, the expression of the tetraspan protein epithelial membrane protein 2 (EMP2) was explored as a predictor of TNBC response to standard chemotherapy. We demonstrate that EMP2 functions as a prognostic biomarker for patients treated with taxane-based chemotherapy, with high expression at both transcriptomic and protein levels following treatment correlating with poor overall survival. Moreover, we show that targeting EMP2 in combination with docetaxel reduces tumor load in syngeneic and xenograft models of TNBC. These results provide support for the prognostic and therapeutic potential of this tetraspan protein, suggesting that anti-EMP2 therapy may be beneficial for the treatment of select chemotherapy-resistant TNBC tumors. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder